par Esther, Angeleena;Alimoradi, Houman 
;Greish, Khaled
Référence Harnessing Endogenous Mechanisms for Targeted Drug Delivery, Elsevier, page (307-339)
Publication Publié, 2025-01
;Greish, KhaledRéférence Harnessing Endogenous Mechanisms for Targeted Drug Delivery, Elsevier, page (307-339)
Publication Publié, 2025-01
Partie d'ouvrage collectif
| Résumé : | Hypoxia, a condition characterized by low oxygen levels, is common in various pathological conditions, especially in solid tumors. It is a key feature of the tumor microenvironment (TME), playing a vital role in angiogenesis, tumor progression, metastasis, and resistance to chemotherapeutic agents and other conventional treatments. Hypoxia-responsive drug delivery systems (HRDDS) were developed to manipulate the hostile TME to shape tumor behavior and improve therapeutic efficacy. In addition to cancer therapy, HRDDS have also been employed to reduce reperfusion injuries in ischemia and deliver antibiotics to hypoxic capsulated abscesses. Developing HRDDS moieties with controlled drug release kinetics and translation of preclinical studies to clinical applications remains a challenge. Despite being in the nascent developmental stages, HRDDS offer a promising outlook in personalized medicine. This chapter explores the significance and evolution of HRDDS, encompassing preclinical research, clinical translations, challenges, and potential scope for future applications. |
